Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Sucampo Pharmaceuticals, Inc. and Abbott today announced positive top-line data from a 48-week phase 3 long-term safety and efficacy clinical trial of lubiprostone in Japanese patients with chronic idiopathic constipation (CIC). The trial demonstrated that lubiprostone was safe and well-tolerated.

30 Nov 2010

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Apricus Biosciences, Inc., announced today that the International Journal of Pharmaceutics, a peer reviewed journal, has published new data on the NexACT technology in their November 2010 issue, based on research conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey in Piscataway, NJ.

30 Nov 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

AMAG updates product label of Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) regarding an update to the product label for Feraheme (ferumoxytol) Injection for intravenous (IV) use.

29 Nov 2010

Superantigens can disrupt immune system, can cause more illnesses

Superantigens, the toxins produced by staphylococcus bacteria, are more complex than previously believed, reveals a team of researchers from the University of Gothenburg in an article published today in the scientific journal Nature Communications. Their discovery shows that the body's immune system can cause more illnesses than realised.

29 Nov 2010

FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV infections than those who received a placebo pill. New England Journal of Medicine, is the first evidence that this new HIV prevention method, called pre-exposure prophylaxis or PrEP, reduces HIV infection risk in people.

24 Nov 2010

iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men

A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men.

24 Nov 2010

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

XenoPort, Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to support a preclinical study of the efficacy and safety of a novel, orally administered prodrug of acamprosate in reducing L-Dopa induced dyskinesias (LID) in a pre-clinical model of Parkinson's disease.

24 Nov 2010

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.

23 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the "Electrochemotherapy 1st International Users' Meeting"(Bologna, Italy, November 19-20, 2010).

23 Nov 2010

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

The Arthritis Foundation and Covidien have joined forces to help advance awareness and support for millions of people suffering from osteoarthritis in the United States.

23 Nov 2010

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office has granted patent #7,829,668, entitled Compositions and methods for modifying toxic effects of proteinaceous compounds.

22 Nov 2010

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Nausea News and Research

Further Reading

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Spectrum's FUSILEV sNDA accepted by FDA for review

AMAG updates product label of Feraheme Injection

Superantigens can disrupt immune system, can cause more illnesses

FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Vertex submits NDA for telaprevir for treating hepatitis C

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

VYTORIN reduces major vascular events in patients with chronic kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News